Immunoadsorption and AT1-Antibody
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (31 March 2019) | Viewed by 235
Special Issue Editor
Special Issue Information
Dear Colleagues,
In recent years, immunoadsorption (IA) has been increasingly recognized as an alternative treatment approach replacing therapeutic plasma exchange (PE) in a variety of neurological, internal, dermatological disorders, and for patients with immunological risks (allo- and auto-antibodies) after solid organ transplantation, transfusion and pregnancy.
Immediate antibody elimination, pulsed induction of antibody redistribution, and immunomodulation are the major forces of efficacy of IA for some diseases. IA can offer therapeutic options with a rapid response for severe acute symptoms, and stable rehabilitation in long-term clinical courses being refractory to drug-based strategies or complicated by drug side effects. IA in these situations must be considered as part of a multimodal or escalating immune treatment strategy in combination or competition with intravenous immunoglobulins, corticosteroids, the full spectrum of immunosuppressive drugs and bioengineered antibodies. With IA, side effects seem to be less frequent, especially those that result from allo-protein substitution with PE can be avoided.
The influence of antibodies (AB) against human leucocyte antigen (HLA) and non-HLA antigens on antibody mediated rejection (AMR) in patients after solid organ transplantation is still discussed controversially. In the last years, autoantibodies (aAB) against Angiotensin II type I-receptors can cause an AMR without detectable AB in serum in patients after kidney and heart transplantation. The removal of pathogenic aAB via IA is better than medication-based treatment.
Prof. Dagmar Barz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Therapeutic apheresis
- Immunoadsorption/plasma exchange
- Alloantibodies
- Autoantibodies
- Detection of antibodies in the lab
- Side effects of immunoadsorption or plasma exchange
- MHC
- Non-HLA-antigens
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
